Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company dedicated to developing and commercializing innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company's mission is to transform vision by pioneering novel, dropless platforms that significantly advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye conditions. Glaukos' global headquarters is located in Aliso Viejo, California.

Glaukos is recognized for pioneering Micro-Invasive Glaucoma Surgery (MIGS) with its iStent family of devices, including iStent, iStent inject W, and iStent infinite, designed to reduce intraocular pressure. The company's product portfolio also includes iDose TR, a sustained-release pharmaceutical implant for glaucoma, and Epioxa/Epioxa HD, a corneal cross-linking therapy for keratoconus, along with the KXL system for corneal health. Glaukos primarily serves ophthalmic surgeons, eye care professionals, hospitals, and surgical centers.

In recent news, Glaukos reported record net sales of $150.6 million in Q1 2026, marking a 41% year-over-year increase, and subsequently raised its full-year 2026 net sales guidance to between $620 million and $635 million. The company also secured a permanent J-code for its Epioxa keratoconus treatment, enhancing reimbursement clarity. Led by Chairman and CEO Thomas W. Burns, Glaukos maintains a strong market position as a leader in MIGS and FDA-approved corneal cross-linking, with significant growth driven by products like iDose TR.